Bone and soft tissue sarcomas account for about 1% of all human cancers. Sarcomas are highly heterogeneous and can be subdivided into more than 70 different diagnoses according to histological subtypes. 50% of patients will relapse after first-line treatment, and usually accompanied by distant metastasis. locally advanced unresectable and metastatic sarcomas are generally considered incurable, and treatment option for advanced sarcoma is limited. Therefore, in depth studies in the mechanism underlying sarcoma progression is critical to provide new therapeutic options and benefit patients.
In recent years, with the development of new experimental methods, high-throughput sequencing technologies, artificial intelligence, and new nanomaterials, the treatment of patients with advanced sarcoma is gradually being further improved. This topic focuses on the molecular and pathway changes in the progress of bone and soft tissue sarcoma, explores new targets, discusses potential new treatment methods, and provides new ideas for solving the current dilemma of sarcoma treatment.
In this topic, we hope to explore the molecular mechanism of sarcoma progression through the application of new technologies and methods and collect potential new treatment methods to deal with the current treatment dilemma of sarcoma. We advocate the clinical transformation of research and encourage researchers to fully discuss and improve the current progress and shortcomings of sarcoma research. We accept manuscripts including original research and review in the following directions:
• Molecular and cellular mechanisms in bone and soft tissue sarcoma development.
• The potential molecular targets and drugs in advanced sarcoma therapy.
• Mechanisms of tumor micro-environment and their association with bone and soft tissue sarcoma.
• Integrated analysis of multi-omics from sarcoma clinical samples.
• Therapeutic strategy for bone and soft tissue sarcoma.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
Bone and soft tissue sarcomas account for about 1% of all human cancers. Sarcomas are highly heterogeneous and can be subdivided into more than 70 different diagnoses according to histological subtypes. 50% of patients will relapse after first-line treatment, and usually accompanied by distant metastasis. locally advanced unresectable and metastatic sarcomas are generally considered incurable, and treatment option for advanced sarcoma is limited. Therefore, in depth studies in the mechanism underlying sarcoma progression is critical to provide new therapeutic options and benefit patients.
In recent years, with the development of new experimental methods, high-throughput sequencing technologies, artificial intelligence, and new nanomaterials, the treatment of patients with advanced sarcoma is gradually being further improved. This topic focuses on the molecular and pathway changes in the progress of bone and soft tissue sarcoma, explores new targets, discusses potential new treatment methods, and provides new ideas for solving the current dilemma of sarcoma treatment.
In this topic, we hope to explore the molecular mechanism of sarcoma progression through the application of new technologies and methods and collect potential new treatment methods to deal with the current treatment dilemma of sarcoma. We advocate the clinical transformation of research and encourage researchers to fully discuss and improve the current progress and shortcomings of sarcoma research. We accept manuscripts including original research and review in the following directions:
• Molecular and cellular mechanisms in bone and soft tissue sarcoma development.
• The potential molecular targets and drugs in advanced sarcoma therapy.
• Mechanisms of tumor micro-environment and their association with bone and soft tissue sarcoma.
• Integrated analysis of multi-omics from sarcoma clinical samples.
• Therapeutic strategy for bone and soft tissue sarcoma.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
